טוען...
Treatment of Newly Diagnosed Myeloma: Bortezomib-based Triplet
In this paper we review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation. Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first line therapy. In one of these trials, VRD demons...
שמור ב:
| הוצא לאור ב: | Semin Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5266536/ https://ncbi.nlm.nih.gov/pubmed/28061990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminoncol.2016.11.003 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|